TY - JOUR
T1 - Physiology and molecular genetics of multidrug resistance in Entamoeba histolytica
AU - Orozco, Esther
AU - Gómez, Consuelo
AU - Pérez, D. Guillermo
N1 - Funding Information:
The authors would like to thank Alfredo Padilla for his help with the artwork. Dr Orozco is an International Fellow of Howard Hughes Medical Institute. This work was also supported by CONACyT (México).
PY - 1999/6
Y1 - 1999/6
N2 - Entamoeba histolytica presents the evolutionarily conserved multidrug- resistance (MDR) phenotype, discovered in mammalian cells. MDR cells overexpress the membrane P-glycoprotein, which excludes unrelated drugs from the cytoplasm. E histolytica mutants exhibit cross-resistance to unrelated drugs, which are pumped out from the cytoplasm. In drug-resistant trophozoites, the constitutively expressed EhPg1 gene appears to be up- regulated by a C/EBP-like factor and a multiprotein complex that were not found in drug-sensitive trophozoites. The drug-induced EhPgp5 gene, on the other hand, appears to be up-regulated by AP-1 and HOX factors. Here we review the main physiological and molecular facts of the MDR phenotype in E. histolytica.
AB - Entamoeba histolytica presents the evolutionarily conserved multidrug- resistance (MDR) phenotype, discovered in mammalian cells. MDR cells overexpress the membrane P-glycoprotein, which excludes unrelated drugs from the cytoplasm. E histolytica mutants exhibit cross-resistance to unrelated drugs, which are pumped out from the cytoplasm. In drug-resistant trophozoites, the constitutively expressed EhPg1 gene appears to be up- regulated by a C/EBP-like factor and a multiprotein complex that were not found in drug-sensitive trophozoites. The drug-induced EhPgp5 gene, on the other hand, appears to be up-regulated by AP-1 and HOX factors. Here we review the main physiological and molecular facts of the MDR phenotype in E. histolytica.
UR - http://www.scopus.com/inward/record.url?scp=0033150369&partnerID=8YFLogxK
U2 - 10.1054/drup.1999.0087
DO - 10.1054/drup.1999.0087
M3 - Artículo
C2 - 11504490
SN - 1368-7646
VL - 2
SP - 188
EP - 197
JO - Drug Resistance Updates
JF - Drug Resistance Updates
IS - 3
ER -